Notice of Change to Application Types Allowed in PAR-23-267 "Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)"
Notice Number:
NOT-TR-24-018

Key Dates

Release Date:

March 4, 2024

Related Announcements

  • April 18, 2023 - Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed). See NOFO PAR-23-267.

Issued by

National Center for Advancing Translational Sciences (NCATS)

Purpose

The purpose of this Notice is to change the application types allowed in PAR-23-267, Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine, to include Renewal (Phase II) applications. 

Part 2. Full Text of Announcement  
Section II. Award Information

Currently reads:

Resubmission (All Phases) 
New (Phase I) 
New (Phase I, Fast-Track) 
New (SBIR Direct Phase II)


Corrected to read (in bold italics):  

Resubmission (All Phases)  
New (Phase I, Fast-Track, Direct Phase II) 
Renewal (Phase II)


All other aspects of the NOFO remain unchanged. 

Inquiries

Please direct all inquiries to:

Christine Happel, Ph.D. 
Office of Special Initiatives 
National Center for Advancing Translational Sciences (NCATS) 
Telephone: 301-827-9444  
Email: [email protected]